At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
AAV - CNGB3biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3
In Brief
A Phase 2 clinical trial evaluating AAV - CNGB3 for Achromatopsia. Completed, enrolled 23 participants across 2 sites in 2 countries.
Detailed Summary
A clinical trial of AAV - CNGB3 retinal gene therapy for patients with achromatopsia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAchromatopsia
CountriesUnited Kingdom, United States
CollaboratorsJanssen Research & Development, LLC
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartJan 2017
Primary CompletionOct 2019
TodayJul 2026
First PostedDec 23, 2016
Enrollment StartJan 16, 2017
Primary CompletionOct 25, 2019
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 9.5 years ago
Interventions
AAV - CNGB3biological
Comparison of different dosages of AAV-CNGB3